Sphingolipid and Endocannabinoid Profiles in Adult Attention Deficit Hyperactivity Disorder

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Sep 28

PMID 34572359

Citations 9

Authors

Nathalie Brunkhorst-Kanaan

Sandra Trautmann

Yannick Schreiber

Dominique Thomas

Sarah Kittel-Schneider

Robert Gurke

Gerd Geisslinger

Andreas Reif

Irmgard Tegeder

Affiliations

Soon will be listed here.

Abstract

Genes encoding endocannabinoid and sphingolipid metabolism pathways were suggested to contribute to the genetic risk towards attention deficit hyperactivity disorder (ADHD). The present pilot study assessed plasma concentrations of candidate endocannabinoids, sphingolipids and ceramides in individuals with adult ADHD in comparison with healthy controls and patients with affective disorders. Targeted lipid analyses of 23 different lipid species were performed in 71 mental disorder patients and 98 healthy controls (HC). The patients were diagnosed with adult ADHD (n = 12), affective disorder (major depression, MD n = 16 or bipolar disorder, BD n = 6) or adult ADHD with comorbid affective disorders (n = 37). Canonical discriminant analysis and CHAID analyses were used to identify major components that predicted the diagnostic group. ADHD patients had increased plasma concentrations of sphingosine-1-phosphate (S1P d18:1) and sphinganine-1-phosphate (S1P d18:0). In addition, the endocannabinoids, anandamide (AEA) and arachidonoylglycerol were increased. MD/BD patients had increased long chain ceramides, most prominently Cer22:0, but low endocannabinoids in contrast to ADHD patients. Patients with ADHD and comorbid affective disorders displayed increased S1P d18:1 and increased Cer22:0, but the individual lipid levels were lower than in the non-comorbid disorders. Sphingolipid profiles differ between patients suffering from ADHD and affective disorders, with overlapping patterns in comorbid patients. The S1P d18:1 to Cer22:0 ratio may constitute a diagnostic or prognostic tool.

Citing Articles

Brain region specific regulation of anandamide (down) and sphingosine-1-phosphate (up) in association with anxiety (AEA) and resilience (S1P) in a mouse model of chronic unpredictable mild stress.

Fischer C, Thomas D, Gurke R, Tegeder I Pflugers Arch. 2024; 476(12):1863-1880.

PMID: 39177699 PMC: 11582197. DOI: 10.1007/s00424-024-03012-0.

Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers.

Zorkina Y, Ushakova V, Ochneva A, Tsurina A, Abramova O, Savenkova V Metabolites. 2024; 14(2).

PMID: 38392971 PMC: 10890164. DOI: 10.3390/metabo14020080.

Untargeted Lipidomics Study of Bipolar Disorder Patients in Serbia.

Jadranin M, Avramovic N, Miladinovic Z, Gavrilovic A, Tasic L, Tesevic V Int J Mol Sci. 2023; 24(22).

PMID: 38003221 PMC: 10671390. DOI: 10.3390/ijms242216025.

Repetitive and compulsive behavior after Early-Life-Pain associated with reduced long-chain sphingolipid species.

Vogel A, Ueberbach T, Wilken-Schmitz A, Hahnefeld L, Franck L, Weyer M Cell Biosci. 2023; 13(1):155.

PMID: 37635256 PMC: 10463951. DOI: 10.1186/s13578-023-01106-3.

Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?.

Martin-Hernandez D, Munoz-Lopez M, Tendilla-Beltran H, Caso J, Garcia-Bueno B, Menchen L Int J Mol Sci. 2023; 24(16).

PMID: 37628815 PMC: 10454107. DOI: 10.3390/ijms241612634.

References

Bortolato M, Mangieri R, Fu J, Kim J, Arguello O, Duranti A . Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry. 2007; 62(10):1103-10. DOI: 10.1016/j.biopsych.2006.12.001. View

Schmitz K, Brunkhorst R, de Bruin N, Mayer C, Haussler A, Ferreiros N . Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis. Acta Neuropathol Commun. 2017; 5(1):42. PMC: 5457661. DOI: 10.1186/s40478-017-0446-4. View

Wilson R, Nicoll R . Endocannabinoid signaling in the brain. Science. 2002; 296(5568):678-82. DOI: 10.1126/science.1063545. View

Lee S, Ripke S, Neale B, Faraone S, Purcell S, Perlis R . Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013; 45(9):984-94. PMC: 3800159. DOI: 10.1038/ng.2711. View

Bradshaw H, Lee S, McHugh D . Orphan endogenous lipids and orphan GPCRs: a good match. Prostaglandins Other Lipid Mediat. 2009; 89(3-4):131-4. PMC: 2740803. DOI: 10.1016/j.prostaglandins.2009.04.006. View

Ross R . The enigmatic pharmacology of GPR55. Trends Pharmacol Sci. 2009; 30(3):156-63. DOI: 10.1016/j.tips.2008.12.004. View

Thapar A, Cooper M, Eyre O, Langley K . What have we learnt about the causes of ADHD?. J Child Psychol Psychiatry. 2012; 54(1):3-16. PMC: 3572580. DOI: 10.1111/j.1469-7610.2012.02611.x. View

Bioque M, Mas S, Costanzo M, Cabrera B, Lobo A, Gonzalez-Pinto A . Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis. Eur Neuropsychopharmacol. 2019; 29(6):786-794. DOI: 10.1016/j.euroneuro.2019.04.005. View

Henriquez-Henriquez M, Acosta M, Martinez A, Velez J, Lopera F, Pineda D . Mutations in sphingolipid metabolism genes are associated with ADHD. Transl Psychiatry. 2020; 10(1):231. PMC: 7359313. DOI: 10.1038/s41398-020-00881-8. View

10.

Hill M, Kumar S, Filipski S, Iverson M, Stuhr K, Keith J . Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry. 2012; 18(10):1125-35. PMC: 4148304. DOI: 10.1038/mp.2012.90. View

11.

Di Marzo V, Despres J . CB1 antagonists for obesity--what lessons have we learned from rimonabant?. Nat Rev Endocrinol. 2009; 5(11):633-8. DOI: 10.1038/nrendo.2009.197. View

12.

Goni F, Alonso A . Sphingomyelinases: enzymology and membrane activity. FEBS Lett. 2002; 531(1):38-46. DOI: 10.1016/s0014-5793(02)03482-8. View

13.

Micale V, Di Marzo V, Sulcova A, Wotjak C, Drago F . Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol Ther. 2012; 138(1):18-37. DOI: 10.1016/j.pharmthera.2012.12.002. View

14.

Pardini M, Krueger F, Koenigs M, Raymont V, Hodgkinson C, Zoubak S . Fatty-acid amide hydrolase polymorphisms and post-traumatic stress disorder after penetrating brain injury. Transl Psychiatry. 2012; 2:e75. PMC: 3309545. DOI: 10.1038/tp.2012.1. View

15.

Landau Z, Pinhas-Hamiel O . Attention Deficit/Hyperactivity, the Metabolic Syndrome, and Type 2 Diabetes. Curr Diab Rep. 2019; 19(8):46. DOI: 10.1007/s11892-019-1174-x. View

16.

Kitatani K, Idkowiak-Baldys J, Hannun Y . The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal. 2008; 20(6):1010-8. PMC: 2422835. DOI: 10.1016/j.cellsig.2007.12.006. View

17.

Monteleone P, Bifulco M, Di Filippo C, Gazzerro P, Canestrelli B, Monteleone F . Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effects. Genes Brain Behav. 2009; 8(7):728-32. DOI: 10.1111/j.1601-183X.2009.00518.x. View

18.

Mullen T, Hannun Y, Obeid L . Ceramide synthases at the centre of sphingolipid metabolism and biology. Biochem J. 2012; 441(3):789-802. PMC: 3689921. DOI: 10.1042/BJ20111626. View

19.

Merrill Jr A, Jones D . An update of the enzymology and regulation of sphingomyelin metabolism. Biochim Biophys Acta. 1990; 1044(1):1-12. DOI: 10.1016/0005-2760(90)90211-f. View

20.

Wu H, Wang X, Gao J, Liang S, Hao Y, Sun C . Fingolimod (FTY720) attenuates social deficits, learning and memory impairments, neuronal loss and neuroinflammation in the rat model of autism. Life Sci. 2017; 173:43-54. DOI: 10.1016/j.lfs.2017.01.012. View